Recombinant DNA Technology Market Report to Generate Substantial Increment in Dollar Opportunities by 2030

0
35

Recombinant DNA technology articulates DNA molecules from two different species that are introduced into the host organism to produce a new genetic combination with broad application. Market Research Future reported that the global recombinant DNA technology market research is expected to attain a CAGR of 4.9% during the forecast 2022-2030.

Recombinant DNA technology has many uses in cultivation, including the production of Bat cotton, which guards plants against pests. It is extensively used in clinical diagnosis, gene therapy, and drug production.

The worldwide recombinant DNA technology market is anticipated to expand over the course of the forecast period as a result of rising demand for recombinant and genetically modified products for human health, nutrition, and agriculture. The use of recombinant DNA technology to address various food, health, and environmental problems will also receive increased government funding, which is anticipated to spur market expansion. Over the course of the forecast period, market growth should be accelerated by manufacturing companies that concentrate on product development using recombinant DNA technology for a range of chronic illnesses.

Regional Analysis

The Americas has the largest share in the global recombinant DNA technology market due to the effective regulation of the registration of recombinant therapeutic products and other genetically modified (GM) products. Presence of some leading key players operating in this sector contributes to the growth of the recombinant DNA technology market in the region.

In addition, there is a growing need to improve recombinant protein production capacity several times in Europe. Growing demand for effective treatments for disease treatment and technological progress in this sector should lead to the growth of the European market for recombinant DNA technology.

The Asia Pacific region is expected to become the fastest-growing regional market for the global recombinant DNA technology market. Raising awareness about the growth of genetic diseases and disorders, developing health infrastructure, increasing healthcare spending, strengthening government initiatives to improve public health, and progress in the medical field stimulates market growth.

The Middle East and Africa are is said to witness limited growth due to declining demand for genetic testing. The Middle East is experiencing significant growth compared to the African recombinant DNA technology market due to growing population, innovations in genetic testing and the growing number of chronic disease cases.

Segmentation

The global recombinant DNA technology market report is broadly segmented based on multiple factors such as product, component, application, and end-user.

The product segment of the global recombinant DNA technology market is bifurcated into medical and non-medical. Further, the medical is sub-segmented into vaccines, therapeutic agents, and human proteins. The non-medical sub-segment is classified into specialty chemicals and biotech crops.

Based on the component, the global recombinant DNA technology market is bifurcated into cloning vector, expression system, and others. The cloning vector sub-segment is divided as Yeast Artificial Chromosome (YAC), plasmid, cosmid, phage, Human Artificial Chromosome (HAC), and Bacterial Artificial Chromosome (BAC). The expression system sub-segment is classified into yeast, bacteria mammalian, and baculovirus/insect.

The application segment of the global recombinant DNA technology market is bifurcated into disease, food and agriculture, environment, and health.

The global recombinant DNA technology market, based on end-users, is also bifurcated as government research institutes, biotechnology companies, pharmaceuticals, and universities.

Major Players

Some of the key players in the global recombinant DNA technology market are F. Hoffmann-La Roche Ltd, Profacgen, Amgen Inc., Pfizer Inc., Novartis AG, Genscript Biotech, Sanofi S.A., Novo Nordisk A/S, Merck & Co., Inc., Biogen Inc., Biocon Limited, Eli Lilly and Company, GlaxoSmithKline plc, Cibus, New England Biolabs, Horizon Discovery Group PLC, Boehringer Ingelheim, Monsanto Company, and others.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com